Stocks · News reference
Zenas BioPharma held an R&D event on October 30, 2026, to detail development plans for its lead candidate obexelimab and its oral IL-17 inhibitor ZB021.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Zenas BioPharma announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical programs, including the ongoing Phase 1 trial of ZB021.
Filed: 2026-11-05 AccNo: 0001104659-26-123035 Size: 282 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Morgan Stanley analyst Chris Yu has initiated coverage on Zenas BioPharma, Inc. with a 'Hold' rating and a price target of $32.
InnoCare Pharma's third quarter 2026 business update highlights the ongoing advancement of global registrational Phase III clinical trials for orelabrutinib in collaboration with Zenas BioPharma.
HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $44 price target.
Zenas BioPharma presented new clinical data for obexelimab at the 6th International Symposium on IgG4-Related Disease. Phase 3 INDIGO open-label extension results showed sustained clinical activity with a 93% probability of remaining flare-free at 12 months, significantly reduced glucocorticoid toxicity compared to placebo, and positive vaccine responses during a treatment-free window. The data supports obexelimab's potential as a steroid-sparing B-cell inhibitor for long-term IgG4-RD management.